A Phase 4 interventional study of 5% Dextrose and Betamethasone and local anesthetic in Carpal Tunnel Syndrome, sponsored by Ankara Etlik City Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Ankara Etlik City Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies in Carpal Tunnel Syndrome with a site in Turkey — 36 open to participants now, 41 under way, none of them phase 3. Carpal Tunnel Syndrome · Turkey.
Among the 130 studies in Carpal Tunnel Syndrome with a site in Turkey, this one is the 52nd largest by enrollment of the 82 interventional ones that give a count, is one of 24 that started in 2025, is one of 5 in phase 4, and was the 92nd registered.
591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.
Browse Carpal Tunnel Syndrome studies →36 of the 130 studies in Carpal Tunnel Syndrome with a site in Turkey are open now. Recruiting first, the newest first:
Izmir Bakircay University · Sites in Turkey
Ages 18–60
Izmir Bakircay University · Sites in Turkey
Ages 18–60
Konya Beyhekim Training and Research Hospital · Sites in Turkey
Ages 18–65 · Healthy volunteers
Haydarpasa Numune Training and Research Hospital · Sites in Turkey
Ages 18–75
Istanbul University · Sites in Turkey
Ages 18–65
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 24 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 60 across 446 interventional studies indexed under Carpal Tunnel Syndrome.
Median enrollment 60 across the 82 interventional studies, 84 across the 48 observational. Of the 82 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 130 has an industry lead sponsor. The 10 most frequent:
Ankara Etlik City Hospital is the lead sponsor of 180 studies on the registry; 77 are open to participants now.
Ankara Etlik City Hospital has 2 studies filed under Carpal Tunnel Syndrome — fewer than ten, so there is no comparison to draw.
12 of the studies in Carpal Tunnel Syndrome with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07433166SB Istanbul Education and Research HospitalUltrasound Evaluation in Carpal Tunnel Syndrome | 2026-12 |
| NCT07327723Ankara UniversityEffects of Repetitive Peripheral Magnetic Stimulation(rPMS) on CTS(Carpal Tunnel Syndrome) | 2026-12-15 |
| NCT07522060Hacettepe UniversityEarly Functional Response as a Predictor of Clinical Outcomes in Hand Rehabilitation: A Prospective Feasibility Study Using a Digital Monitoring System | 2026-12-30 |
| NCT07847450Bezmialem Vakif UniversityMeasurement of Muscle Strength Using a Manual Muscle Tester in Women With Electrophysiologically Confirmed Carpal Tunnel Syndrome | 2027-01 |
| NCT07359274Kutahya Health Sciences UniversityEffects of Neurodynamic and Carpal Bone Mobilization in Mild-to-Moderate Carpal Tunnel Syndrome | 2027-01-15 |
Add all 12 to your calendar (.ics) → With an account.
Among the 130 studies in Carpal Tunnel Syndrome with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to compare the effects of ultrasound-guided hydrodissection with 5% dextrose and perineural corticosteroid injection on the clinical parameters of carpal tunnel syndrome, as well as to evaluate the long-term efficacy of these treatments.
Carpal tunnel syndrome (CTS), the most prevalent peripheral compressive neuropathy, manifests primarily with sensory disturbances such as pain, numbness, and nocturnal paresthesia. Treatment options for CTS differ considerably depending on the severity of symptoms, and typically include splinting, physiotherapy, local injection therapies, and surgical release. Hydrodissection is an ultrasound-guided technique that has recently gained increased attention for its role in the management of nerve entrapment syndromes. The technique uses fluid injection to separate the nerve from nearby tissues. This may reduce perineural adhesions and improve the patient's symptoms. In hydrodissection, normal saline, 5% dextrose, or platelet-rich plasma (PRP) can be used as injectates. Recently, hydrodissection with 5% dextrose has become the most commonly used approach. Several studies in the literature have demonstrated that perineural hydrodissection with 5% dextrose provides more favorable outcomes than corticosteroid injections in patients with mild to moderate CTS, particularly at 4 to 6 months post-injection. However, it remains unclear whether hydrodissection leads to a reduction in the cross-sectional area of the median nerve. In addition, studies examining the procedural details of hydrodissection are limited. Therefore, further clinical research is needed to better understand and validate the technique.
Ultrasound-guided hydrodissection for CTS is performed using a 12 MHz linear array transducer probe (GE Logiq P9, GE Healthcare, Boston, MA). The median nerve (MN) is visualized at the scaphoid-pisiform level. In the intervention group, 2.5 ml of 5% dextrose is injected via an in-plane ulnar approach to separate the MN from the transverse carpal ligament, followed by an additional 2.5 ml of normal saline (NS) injected to separate the MN from the flexor tendons. In the control group, perineural injection of 1 ml betamethasone is administered around the MN using the same ultrasound device and probe.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Presence of at least one of the following symptoms lasting more than one month:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the hydrodissection group will undergo ultrasound-guided perineural hydrodissection of the median nerve at the scaphoid-pisiform level using a 12 MHz linear transducer (GE Logiq P9, GE Healthcare, Boston, MA). Under sterile conditions, 2.5 ml of 5% dextrose will be injected via an in-plane ulnar approach to mechanically separate the median nerve from the transverse carpal ligament. Subsequently, an additional 2.5 ml of 5% dextrose will be administered to separate the nerve from adjacent flexor tendons. The total injection volume will be 5 ml.
Drug: 5% Dextrose
Participants in the corticosteroid group will undergo ultrasound-guided perineural injection of the median nerve at the scaphoid-pisiform level using a 12 MHz linear transducer (GE Logiq P9, GE Healthcare, Boston, MA). A perineural injection of 1 ml betamethasone combined with 1 ml 2% lidocaine will be administered around the median nerve.
Drug: Betamethasone and local anesthetic
Ultrasound-guided hydrodissection is performed using a 12 MHz linear transducer (GE Logiq P9, GE Healthcare) via an in-plane ulnar approach under sterile conditions. 2.5 ml of 5% dextrose will be injected via an in-plane ulnar approach to mechanically separate the median nerve from the transverse carpal ligament. Subsequently, an additional 2.5 ml of 5% dextrose will be administered to separate the nerve from adjacent flexor tendons. The total injection volume will be 5 ml.
Drug pages: BetamethasoneStudies of BetamethasoneBetamethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Local anestheticsStudies of Local anestheticsLocal anesthetics pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Ultrasound-guided perineural injection is performed using a 12 MHz linear transducer (GE Logiq P9, GE Healthcare) via an in-plane ulnar approach under sterile conditions. A total of 2 ml solution (1 ml betamethasone and 1 ml 2% lidocaine) is injected perineurally around the median nerve under ultrasound guidance at the scaphoid-pisiform level.
Boston Carpal Tunnel Questionnaire
The Boston Carpal Tunnel Questionnaire (BCTQ) is a validated disease-specific assessment tool developed in 1993 to provide standardized clinical evaluation of carpal tunnel syndrome (CTS). It comprises 19 items divided into two subscales: the Symptom Severity Scale (BCTQ-SSS) and the Functional Status Scale (BCTQ-FSS). Scores on both subscales range from 1 to 5, with higher scores reflecting increased symptom burden and functional impairment associated with CTS.
Time frame: At baseline, at Month 1,3,6 (Visit 1,2,3)
Visual Analog Scale (VAS)
Patients rate their pain on a 0-10 scale. A lower score indicates reduced pain.
Time frame: At baseline and at Month 1,3,6 (Visit 1,2,3)
Cross-Sectional Area (CSA) of the Median Nerve via Ultrasonography
Median nerve CSA will be measured at the scaphoid-pisiform level. A reduction in CSA indicates improvement.
Time frame: At baseline and at month 3,6 (Visit 2,3)
Hand Grip Strength
Hand grip strength will be measured using a standard Jamar dynamometer. During the procedure, patients will be seated with the elbow flexed at 90° and the forearm in a neutral position. Three consecutive measurements will be taken, and the average value will be recorded. Improvement reflects functional recovery.
Time frame: At baseline and at Month 3,6 (Visit 2,3)
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2025 to primary completion in Mar 2026, 7 months.
Of 28 non-industry phase 4 interventional studies under Carpal Tunnel Syndrome, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 19. This study's 7 months is close to that.
Counting every sponsor, half of 28 studies reached it within 7 months; a quarter within 3 and three quarters within 19.
Primary completion moved once since we started tracking on Sep 25, 2026: Feb 2026 → Mar 2026, on Nov 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Glucose · Betamethasone · Local anesthetics